31 results
8-K
EX-99.1
APVO
Aptevo Therapeutics Inc
19 Sep 22
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND
9:14am
and is a testament to the strength of our partnership with Aptevo. This new IND also demonstrates our ability to bring innovative antibodies … ," “innovative,” “initiate,” “allow,” "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking
8-K
EX-99.1
tmwl0da 4to8
12 May 22
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and One patient received APVO436 in a monotherapy cohort of the trial and experienced significant reduction in bone marrow blasts
8:15am
8-K
EX-9.1
lgf 7jz4bradwn
29 Mar 22
Other Events
8:15am
8-K
EX-99.1
slfvbpwx
24 Mar 22
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
8:15am
8-K
EX-99.1
tcgxbzxc9yjmza8j6rg
9 Feb 22
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE®, Provides Company Update
8:16am
8-K
EX-99.1
gz4vuw 8i390wd
21 Jan 22
Departure of Directors or Certain Officers
8:15am
8-K
EX-99.1
zupaoqmrcy2sups
23 Nov 21
Other Events
8:18am
8-K
EX-99.1
alcv37ma
12 Nov 21
Aptevo Therapeutics Reports Third Quarter Financial Results with Business Highlights
8:16am
8-K
EX-99.1
ikw9fau40 rh
17 Aug 21
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
8:35am
8-K
EX-99.1
hogcbnceqb v5fsiy
12 Aug 21
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
4:11pm
8-K
EX-99.1
aesl06vnc ehkf5s
27 May 21
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-leukemia Drug APVO436 In Adult Patients with Acute Myeloid Leukemia
9:02am
8-K
EX-99.1
rg8du
26 May 21
Regulation FD Disclosure
9:00am
DEFC14A
u80lcefx4 erv
11 May 21
Proxy in contested solicitation
8:55am
PREC14A
5eeuv9 rnmc8cs
28 Apr 21
Preliminary proxy with contested solicitation
4:20pm